Rectal brachytherapy boost to try to avoid surgery for low-lying residual rectal cancer after total neoadjuvant therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Patients with incomplete or near-complete responses after standard total neoadjuvant therapy will undergo pelvic MRI and sigmoidoscopy with marker placement to define residual tumor for planning. A multichannel rectal cylinder is positioned under local analgesia, a balloon is inflated to displace uninvolved rectum, and three weekly outpatient brachytherapy sessions deliver a total of 21 Gy targeted to the high‑risk mucosa at a depth matching tumor thickness. The cylinder may be immobilized for up to three hours during each session while radiation delivery itself takes under ten minutes, and patients who achieve a complete response enter standard nonoperative surveillance with aligned study visits for two years. Although rectal brachytherapy has prior safety and efficacy data from Europe and Canada, this protocol specifically tests its role as a boost after total neoadjuvant therapy in U.S. centers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provision to sign and date the consent form.
2. Stated willingness to comply with all study procedures and be available for the duration of the study.
3. Adults (18-100 years old)
4. ECOG 0-3
5. Patients with MMR-proficient low-mid rectal adenocarcinoma cT1-4 N0-2 M0 who underwent total neoadjuvant therapy who have not achieved complete response (i.e. incomplete or near-complete) in the rectal primary tumor such that surgical resection, if offered presently or in the future, would be an APR or low LAR per colorectal surgeon expert opinion and central review at University of Colorado rectal tumor board. Tumor restaging will be 4-16 weeks following completion of total neoadjuvant therapy, and no sooner than 8 weeks if patients received chemotherapy followed by chemoradiation/short course radiation.
6. Residual rectal disease must have its craniocaudal extent \<4 cm with thickness \<1.2 cm. Tumor must have \<50% circumferential involvement. Residual disease must be above the dentate line and not involving the anal canal.
7. In patients with original cN1-2 disease, restaging CT and MRI after total neoadjuvant therapy must demonstrate at least near-complete response of the pelvic lymph nodes per NCCN criteria as evaluated by central review at University of Colorado rectal tumor board.
8. Interval of time between completion of TNT and initiation of rectal brachytherapy must be between 4-16 weeks.
9. Patients must be recovered from total neoadjuvant therapy and must not have significant rectal incontinence at time of screening.
10. Received conventionally fractionated external beam chemoradiation between 45-56 Gy or short-course external beam radiation prescription of 25 Gy to rectal mucosa, in addition to systemic chemotherapy before or after radiation per National Comprehensive Cancer Network (NCCN) guidelines.
11. Women of child-bearing potential must have a negative urine or serum pregnancy test within 14 days of HDR treatment.
12. Men and women of reproductive potential who are sexually active must agree to follow instructions of contraception for the duration of the study and 6 months post-rectal brachytherapy completion.
13. CBC at the time of screening must have platelets\>50 10\^9/L, Hemoglobin\>8 g/dL and Absolute Neutrophil Count \> 500 10\^9/L

Exclusion Criteria:

1. History of ulcerative colitis or Crohn's disease.
2. Pelvic radiotherapy given prior to rectal cancer external beam radiation.
3. Prior colorectal surgery in which anastomotic site is at or near HDR brachytherapy target.

   o Prior local excision is not an exclusion criterion.
4. Uncontrolled intercurrent severe illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
5. Life expectancy \<3 years per provider discretion.
6. Concurrent administration of any cytotoxic chemotherapy, immunotherapy, or other any targeted oncologic agent that would impact rectal cancer is not allowed during study protocol.
7. If rectal cancer has been treated outside of standard total neoadjuvant therapy per NCCN guidelines, patients are ineligible for the trial. This includes if patients received external beam chemoradiation dose with prescription \>56 Gy or short-course radiation to rectal mucosa prescription \>30 Gy.
8. Pregnant women.

Where it's running

• University of Colorado Cancer Center
  Aurora, Colorado, United States Recruiting
• University of Rochester Medical Center
  Rochester, New York, United States Not yet recruiting
• Oregon Health and Sciences University
  Portland, Oregon, United States Not yet recruiting

Study contacts

• Principal investigator: David Binder — University of Colorado, Denver
• Study coordinator: Radiation Therapy Group
• Email: RTClinicalResearch@olucdenver.onmicrosoft.com
• Phone: 303-724-8822

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Short-course pelvic radiotherapy followed by CAPOX (capecitabine + oxaliplatin) and bevacizumab, with or without PD‑1 immunotherapy, for locally advanced rectal cancer.

  This trial tests whether adding a PD‑1 immunotherapy to short-course radiotherapy followed by CAPOX and bevacizumab helps adults with locally advanced rectal cancer get a higher complete response rate and fewer distant metastases.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07198165

• Database for managing rectal cancer patients with a watch-and-wait approach

  This study is trying to gather information from rectal cancer patients in Asia who are closely monitored after treatment to see if the watch-and-wait approach is safe and effective for them.

  Recruiting Tata Memorial Centre · Mumbai, Maharashtra · NCT06631443

• Nonoperative management of rectal cancer after neoadjuvant therapy

  This study is testing if people with rectal cancer who have a complete response to initial treatment can safely avoid surgery and still do well in terms of their health and quality of life.

  Recruiting at 13 sites Tampere University Hospital · Tallinn and 12 other locations · NCT06328361

• Combining Tucatinib and Trastuzumab for HER2 Positive Rectal Cancer

  This study is testing if combining two cancer drugs, tucatinib and trastuzumab, with standard chemotherapy can help people with HER2 positive rectal cancer have better treatment results.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05672524

• Single vs. double stapling and purse-string techniques after rectal cancer surgery

  This trial tests whether using a single-stapling method to join the bowel after rectal cancer surgery results in fewer leaks compared with the double-stapling method.

  Recruiting Alexandria University · Alexandria · NCT07929415

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.